Secondary neonatal iron overload occurs with intrauterine and post-natal bloodtransfusions. Treatment with intravenous Deferoxamine was reported only infour cases in the literature. Herein we report a case of a patient born at 36weeks of gestation, who had rhesus hemolytic disease. He developed secondaryiron overload, causing liver injury, after a total of six blood transfusions: fourintrauterine and 2 post-natal transfusion therapies. Intravenous Deferoxaminetreatment was started at the age of 45 days due to a ferritin level of 40,000mg/L, progressive rise of liver enzymes, and worsening cholestasis. Treatmentresulted in marked reduction in ferritin level (down to 829 mg/L at the ageof 6 months), significant improvement in the liver enzymes, and resolutionof cholestasis
___
1. Aygun C, Tekinalp G, Gurgey A. Increased fetal iron load in rhesus hemolytic disease. Pediatr Hematol Oncol 2004; 21: 329-333.
2. Craparo FJ, Bonati F, Gementi P, Nicolini U. The effects of serial intravascular transfusions in ascitic/ hydropic RhD-alloimmunized fetuses. Ultrasound Obstet Gynecol 2005; 25: 144-148.
3. Smits-Wintjens VE, Rath ME, Lindenburg IT, et al. Cholestasis in neonates with red cell alloimmune hemolytic disease: Incidence, risk factors and outcome. Neonatology 2012; 101: 306-310.
4. FBadran E, Al-lawama M, Masri A, Al-Amouri I, Al Kazaleh F. Fetal intrauterine transfusion therapy: Neonatal outcomes. J Blood Lymph 2013; 3: 112.
5. Demircioglu F, Caglayan Sozmen S, Yilmaz S, et al. Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications. Turk J Haematol 2010; 27: 204-208.
6. Sreenan C, Idikio HA, Osiovich H. Successful chelation therapy in a case of neonatal iron overload following intravascular intrauterine transfusion. J Perinatol 2000; 20: 509-512.
7. Yilmaz S, Duman N, Ozer E, et al. A case of rhesus hemolytic disease with hemophagocytosis and severe iron overload due to multiple transfusions. J Pediatr Hematol Oncol 2006; 28: 290-292.
8. Yalaz M, Bilgin BS, Koroglu OA, et al. Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant. Eur J Pediatr 2011; 170: 1457-1460.
9. Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64 :154-168.
10. Feldman AG, Whitington PF. Neonatal hemochromatosis. J Clin Exp Hepatol 2013; 3: 313-320.
11. Botzenhardt S, Li N, Chan EW, Sing CW, Wong IC, Neubert A. Safety profiles of iron chelators in young patients with haemoglobinopathies. Eur J Haematol 2017; 98: 198-217.
12. Mobarra N, Shanaki M, Ehteram H, et al. A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res 2016; 10: 239-247.
13. Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusiondependent thalassemia syndromes. Drug Des Devel Ther 2016; 10: 4073-4078.
14. Thorp JA, O'Connor T, Callenbach J, et al. Hyporegenerative anemia associated with intrauterine transfusion in rhesus hemolytic disease. Am J Obstet Gynecol 1991; 165: 79-8